Finding protein plaques associated with Alzheimer’s disease can often require costly PET scans or invasive spinal taps.
But researchers at Cedars-Sinai Medical Center, in conjunction with Sacramento-based NeuroVision Imaging, announced Tuesday they have discovered a way to detect and identify the disease by optically scanning eyeballs.
In a peer-reviewed study published in “JCI Insight” last week, the scientists said they were able to employ experimental retinal imaging to detect and identify the beta-amyloid protein deposits that mirror those lodged in the brain.
It was the first feasibility study to noninvasively detect the protein plaques in retinas of living patients.
The non-invasive technology, researchers said, potentially allows for early screening, detection and treatment of the debilitating cognitive disease.
Findings from the Cedars-Sinai/NeuroVision study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimers, researchers said. Clinical trials are ongoing.
Funding for the study was provided by the National Institutes of Health, the National Institute on Aging, the Saban Family Foundation and the Marciano Family Foundation.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Alzheimer’s Test Sports New Look
- Alzheimer’s Eye Test Firm Raises $11M
- Imaging Clinic Sees Profits With Alzheimer’s Test
- Cedars-Sinai Awarded $12 Million to Study Deadly Lung Diseases
- Gifts for Cedars-Sinai Accelerator Grads: Contracts
- Cedars-Sinai Joins Forces With Salix Pharmaceuticals to Research Gut Disorders
- Harbor Freight Mogul Gives $50M to Cedars-Sinai for Heart Research